Kester Capital is a leading UK private equity investor focused on Healthcare, Information & Data, and Technology businesses that require capital to unlock their potential.
> £5 million
Portfolio companies supported by bolt-on acquisitions
> 100 years
Collective investment experience
Employed across portfolio
GXP Engaged is a leading provider of Good Clinical/Pharmacovigilance Practice (GCP/GVP) audit and related consulting services to the pharmaceutical and biotech sectors. The business has an exceptional reputation for quality and is well-positioned to benefit from strong market tailwinds, including an increasingly onerous and rigorously enforced regulatory environment, the continued growth of the global drug development pipeline, and the increasing propensity of biopharma to outsource non-core functions.
MAP is a leading provider of market access consulting services to the pharmaceutical and biotech sectors, with expertise in rare and orphan diseases and cell and gene therapies. The business is dedicated to accelerating patient access to ground-breaking medicines, devices, and diagnostics, and has a proven track record of helping its customers navigate increasingly complex healthcare reimbursement processes around the world. MAP’s consulting services are supported by its proprietary digital platform, MAP Online, which provides actionable market access intelligence to industry participants.
DC Byte is the leading provider of global market data and analytics for the data centre sector. The company’s platform provides a unique view of the market by covering both colocation and self-build enterprise assets. Research is aggregated by the world’s largest dedicated team of data centre analysts. All data is continually validated in real time and combined with a range of proprietary cutting-edge analytics tools making it a must-have for anyone seeking accurate and insightful market intelligence.
Rephine is a leading provider of Good Manufacturing Practice (GMP) audits and regulatory consulting services to the pharmaceutical industry. The business has pioneered a differentiated approach to GMP auditing through its audit library model, solving common manufacturer and customer pain points caused by increasingly time-consuming and onerous auditing requirements. With pharmaceutical supply chains and regulations continuing to grow in complexity, the business is well-positioned to benefit from strong market tailwinds.
Optibrium is a leading drug discovery software provider to the pharmaceutical and biotech industries. The market for computer aided drug discovery (CADD) is valued at >£2 billion and is projected to grow at double digit rates in the medium term. Its StarDrop product is a complete platform of integrated software for small molecule design, optimisation and data analysis that enhances the speed and productivity of the drug discovery process. Optibrium’s recently launched Cerella product uses artificial intelligence to learn from complex drug discovery data to target high-potential chemical compounds. The business’ customer base includes five of the top ten global pharmaceutical companies.
YouGarden is a direct to consumer home shopping platform focusing on the gardening sector through its business to consumer brand YouGarden and a number of business to business category management partnerships with established brands including Ideal World TV shopping and Amazon Prime. Launched in 2012, YouGarden offers consumers a range of live plants, flowers, trees and bulbs which it sources from across the UK and Europe.
VIXIO is the world’s leading provider of global regulatory intelligence to the gambling and payment sectors through its Gambling Compliance, Payments Compliance and RegData products. The business enables compliance and legal teams around the world to manage risk confidently and discover new market opportunities by providing in-depth insight, analysis, commentary and research. Since inception in 2007, VIXIO has been at the forefront of the gambling regulatory landscape, growing its subscription-based information services at an exceptional rate, and, in 2015, it launched a similar offering for the payments industry.
Jollyes Retail Group Limited (“Jollyes”), is the UK’s second largest pet retailer. Founded in 1935, Jollyes has a growing portfolio of over 70 retail park superstores and concessions in garden centres across the UK. Jollyes focuses on providing its loyal and growing customer base with pet products and services that combine great quality and value. Jollyes has recently expanded its offering to customers to include grooming and veterinary services in store.
Atec Group is an innovator in personal and commercial insurance distribution. Since inception, Atec Group has been at the forefront of tech-enabled insurance distribution and niche product and channel development. Atec Group has been successful at leveraging its online broking platform, diverse range of insurer relationships, strong digital marketing skills and deep data insights to develop market leading positions and recurring customer relationships in its core markets and channels.
Avania (formerly Factory-CRO) is a leading contract research organisation (“CRO”) focused exclusively on the fast-growing medical device market in Europe, Australia and North America. Founded in 1994, the business offers a full suite of trial management services to its global client base across a broad range of therapeutic areas, including orthopaedic, cardiovascular, dermatology and aesthetics.
The market for medical device CROs is growing quickly, driven by an increasingly stringent regulatory regime, underlying growth in medical device sales and an increasing propensity to outsource.
Avania (formerly Factory-CRO) is Kester Capital’s second investment in the CRO market after its successful investment in Chiltern International.
Frontier Medical Group is a diversified medical devices business focused on the Skin/Wound Care and Infection Prevention markets. The business’ Skin/Wound Care brands include Repose®, Toto® and DermisPlus® which are used in the prevention and treatment of pressure ulcers (bed sores) and treatment of wounds. Through its Infection Prevention division, the business produces a range of sharps and clinical waste containers (Sharpsafe® and Clinisafe) for the safe disposal of medicinal sharps, pharmaceuticals and other clinical waste. Frontier has an established direct sales team in the UK and has recently invested in direct sales teams in the US and Germany to complement it’s expanding global distributor network.
Frontier Medical Group was sold to Agilitas Private Equity in June 2021, delivering a return of 3.4x to Kester Capital funds and a 30% IRR.
AgriBriefing was established to acquire business-to-business media assets with strong market positions. During Kester Capital's ownership, AgriBriefing made five acquisitions across three sectors: agriculture, healthcare and media strategy. AgriBriefing's agriculture assets formed the UK's leading agriculture information and events group.
AgriBriefing was sold to Lyceum Capital in July 2015, delivering an unlevered return of 3.5x to Kester Capital funds and a 57% IRR.
AgriBriefing was formerly known as BriefingMedia.
Garrets International (“Garrets”) is the global leader in outsourced marine catering management for the commercial shipping industry. Garrets manages approximately 1000 vessels on behalf of some of the largest names in world shipping. The market for outsourced marine catering management is in the early stages of development but is growing rapidly due to the increasing awareness of the benefits of outsourcing which include quality and cost control as well as crew welfare and regulatory compliance.
Garrets was sold to Wrist Ship Supply in January 2016, delivering a return of 3.2x to Kester Capital funds and a 38% IRR.
Our Managing Partners have worked together since 2002 and our investment team collectively brings over 100 years of investment experience.
Adam co-founded Kester Capital in 2007 and sits on the firm's Investment Committee.
He previously spent 5 years at European private equity firm Silverfleet Capital, where he focused on mid-market buy-outs. Prior to that, he spent 3 years at Bridgepoint Capital and started his career in the Leveraged Finance team of Deutsche Bank. He currently sits on the boards of Avania (formerly Factory-CRO), Jollyes, Optibrium, Rephine, MAP Patient Access and GXP Engaged.
Adam graduated from Trinity College, Oxford with a degree in Classics.
Cameron co-founded Kester Capital in 2007 and sits on the firm's Investment Committee.
He previously spent 6 years at European private equity firm Silverfleet Capital, where he focused on mid-market buy-outs. Prior to that he spent several years at Bankers Trust as part of the Leveraged Finance team and as a Strategy Consultant with Accenture. He currently sits on the boards of Atec Group, YouGarden and DC Byte.
Cameron graduated from the University of Cape Town with a first class honours degree in Electrical Engineering.
Peter joined Kester Capital in 2019 having previously spent 8 years working in lower mid-market private equity firm, Spring Ventures, and 3 years with technology venture capital investor Blenheim Chalcot. Prior to that, he spent 4 years at Oliver Wyman where he worked as a strategy consultant in the financial services practice. He currently sits on the boards of YouGarden, Optibrium, DC Byte, MAP Patient Access and IGF, an SME asset-based lender.
Peter graduated from St Edmund Hall, Oxford, with degrees in Maths and Economics.
Thomas joined Kester Capital in 2021 having previously spent 7 years in private equity working for Chiltern Capital and Vitruvian Partners. Prior to that, he spent 3 years in corporate finance at Livingstone Partners (now Arrowpoint Advisory) following 4 years at PwC. He currently sits on the board of Rephine and GXP Engaged.
Thomas graduated from the University of Cambridge with a degree in Engineering and Management Studies, and is a Chartered Accountant.
Chief Operating Officer
Chief Operating Officer
Patricia previously spent 18 years at international private equity firm Livingbridge, where she worked within finance and operations.
Patricia graduated from the University of Cape Town with a honours degree in Business Science.
Rob joined Kester Capital in 2021 having previously spent 6 years working in venture capital and private equity with Albion Capital and Root Capital. Prior to that, he spent 4 years at KPMG, working in the corporate finance and restructuring teams.
Rob graduated from the Newcastle University with a first class honours degree in Business Management, and is a Chartered Accountant.
Ben joined Kester Capital in 2018.
He previously spent 3 years in the corporate finance team at PwC, where he focused on UK technology, media and telecoms. Prior to that, he spent several years at Arma Partners, a technology advisory boutique, with a focus on software and IT services. He currently sits on the board of Jollyes.
Ben graduated from the University of York with a degree in Politics, Philosophy & Economics, and is a Chartered Accountant.
James joined Kester Capital in 2023, having worked in private equity since 2018.
Prior to joining, he worked at Limerston Capital and Ares Management Corporation, where he was an investment professional covering multiple sectors and European geographies. James started his career at Citigroup, where he spent 5 years in their Investment Banking division.
James has received an MBA from the London Business School and a BA with honours from the University of Cambridge.
Cam joined Kester Capital in 2023.
He previously spent 5 years at Skill Capital, leading the firm’s B2B software & services franchise and partnering with entrepreneurs on early stage, growth capital and leveraged buyout investments.
Cam graduated from the University of Bristol with a degree in Biological Sciences.
Daisy joined Kester Capital in 2022.
She previously spent over 3 years at Strategy&, the strategic consulting arm of PwC. At Strategy&, Daisy worked on range of projects with a particular focus on the healthcare sector.
Daisy graduated from the University of Cambridge with a degree in Geography.
David joined Kester Capital in 2021.
He previously spent over 4 years at PwC, originally qualifying as a Chartered Accountant in their assurance practice and latterly working in the Healthcare M&A team, advising on transactions across a range of healthcare subsectors.
David graduated from the University of Birmingham with a first class honours degree in Business Management.
Jack joined Kester Capital in 2021.
He previously spent over 5 years at KPMG, latterly within the corporate finance team focused on business services and technology. Prior to that, he started his career in their dedicated private equity assurance practice.
Jack graduated from the University of Durham with a degree in Economics and is a Chartered Accountant.
Hana is an Executive Assistant with extensive experience, having held positions in the legal, accountancy and fitness industries. She has a broad range of skills to call upon to help those around her achieve their best.
Hana graduated in Business and Management Finance (focusing on Crisis Management).
She is fluent in English, Czech and German.
We focus on partnering with talented teams and providing first time institutional capital to ambitious UK businesses with potential for growth.
Our team combines an entrepreneurial approach with an extensive investment track record and works closely with an established network of experienced industry operators.
We partner closely with ambitious management teams, providing a high level of strategic support to accelerate their growth.
Working together since 2002, our partners have a long track record of delivering growth in UK businesses and achieving successful exits. Our team collectively brings over 100 years of investment experience.
A powerful combination of financial firepower and business support drives the organic and acquisitive growth of our investee companies.
We are committed to responsible and sustainable investment. Our investee companies have also been recognised for successfully embedding Environmental, Social and Corporate Governance practices into their commercial activity.
Kester Capital's latest fund is an Article 8 fund under the EU's SFDR regulations and Kester Capital observes the UN-supported Principles for Responsible Investment (“PRI”).
UK SMEs with ambition, talent and strong growth potential
Focused on Healthcare, Information & Data, and Technology
Enterprise value of £10-100 million
First time institutional capital
> £5 million
Kester Capital completes sixth Life Science services deal
Kester Capital portfolio company Optibrium acquires BioPharmics, expanding its 3D drug design and visualisation software offering
Kester Capital backs management buy-out of MAP Patient Access